Jack Yang

Mr. Jack Yang

Boston Medical Center, Boston, Massachusetts, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Neuropharmacology
Verified
Journal Article
Closed access
HNHana Na
Hana Na
QGQini Gan
Qini Gan
LMLiam Mcparland
Liam Mcparland
JYJack Yang
Jack Yang
HYHongbo Yao
Hongbo Yao
WQWendy Qiu
Wendy Qiu

1 January 2021 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Open access
PDF file
HNHana Na
Hana Na
HTHua Tian
Hua Tian
ZZZhengrong Zhang
Zhengrong Zhang
QLQiang Li
Qiang Li
JYJack Yang
Jack Yang
WQWendy Qiu
Wendy Qiu
Intraperitoneal injection of amylin or its analog reduces Alzheimer’s disease (AD) pathology in the brains. However, self-injecting amylin analogs is difficult for patients due to cognitive deficits. This work aims to study the effects of amylin on the brain could be achieved by oral delivery as some study reported that amylin receptor may be present in the gastrointestinal tract. A 6-week course of oral amylin treatment reduced components of AD pathology, including the levels of amyloid-β, phosphorylated tau, and ionized calcium binding adaptor molecule 1. The treatment reduced active forms of cyclin-dependent kinase 5. Oral amylin treatment led to improvements in social deficit in AD mouse. Using immunofluorescence, we observed the amylin receptor complexed with the calcitonin receptor and receptor activity-modifying proteins in the enteric neurons. The study suggests the potential of the oral delivery of amylin analogs for the treatment of AD and other neurodegenerative diseases through enteric neurons.

6 April 2024 in Tomography
Verified
Journal Article
Open access
PDF file
JYJack Yang
Jack Yang
LPLauren Powlovich
Lauren Powlovich
DMDavid Moore
David Moore
LMLinda W. Martin
Linda W. Martin
BMBraden Moore Miller
Braden Moore Miller
Jaime MataJaime Mata
Jaime Mata
Focused ultrasound (FUS) is a minimally invasive treatment that utilizes high-energy ultrasound waves to thermally ablate tissue. Magnetic resonance imaging (MRI) guidance may be combined with FUS (MRgFUS) to increase its accuracy and has been proposed for lung tumor ablation/debulking. However, the lungs are predominantly filled with air, which attenuates the strength of the FUS beam. This investigation aimed to test the feasibility of a new approach using an intentional lung collapse to reduce the amount of air inside the lung and a controlled hydrothorax to create an acoustic window for transcutaneous MRgFUS lung ablation. Eleven pigs had one lung mechanically ventilated while the other lung underwent a controlled collapse and subsequent hydrothorax of that hemisphere. The MRgFUS lung ablations were then conducted via the intercostal space. All the animals recovered well and remained healthy in the week following the FUS treatment. The location and size of the ablations were confirmed one week post-treatment via MRI, necropsy, and histological analysis. The animals had almost no side effects and the skin burns were completely eliminated after the first two animal studies, following technique refinement. This study introduces a novel methodology of MRgFUS that can be used to treat deep lung parenchyma in a safe and viable manner.

3 September 2022 in Tomography
Verified
Journal Article
Open access
PDF file
MCMarcia Costa
Marcia Costa
CFCarolina Fernandes
Carolina Fernandes
MEMatt Eames
Matt Eames
AHArik Hananel
Arik Hananel
JMJohn P. Mugler
John P. Mugler
Jaime MataJaime Mata
Jaime Mata
A combination of surgery and chemotherapy is the most effective treatment available for Malignant Pleural Mesothelioma (MPM). However, both cause significant collateral damage and cannot eliminate residual microscopic disease. This investigation aimed to compare and determine the feasibility of utilizing Radiofrequency Ablation (RFA) and Magnetic-Resonance-guided Focused Ultrasound Surgery (MRgFUS) as alternative treatments for MPM. A large animal tumor model was developed in 13 Yorkshire female pigs using the MSTO211H cell line. Two pigs were initially used to determine the cyclosporine dose required for immunosuppression and tumor development. Subsequently, 11 other pigs underwent tumor development. Of these 11, 2 died during cell inoculation. Small tumor masses and adhesions were present in the other 9, indicating mesothelioma development. Five pigs then received RFA treatment, and 4 pigs received MRgFUS treatment. Tumor model development and effect of the two treatments were examined using MRI and by necropsy. RFA and MRgFUS both successfully ablated approximately the same sized area in the same treatment time. This study demonstrates that RFA and MRgFUS are feasible for tumor debulking, and while MRgFUS requires more pretreatment planning compared to RFA, MRgFUS is a completely noninvasive procedure.